Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indus Obtains FDA Approval For AIDS Molecule Trials
The US Food and Drug Administration (USFDA) has approved Indus Biotech to conduct clinical trails for its molecule, IND02, reported The Economic Times. The newly developed molecule is
The US Food and Drug Administration (USFDA) has approved Indus Biotech to conduct clinical trails for its molecule, IND02, reported The Economic Times. The newly developed molecule is
Solvay Pharmaceuticals has announced that new data demonstrate that Creon (pancrelipase) delayed-release capsules improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due
Pharmaceutical design specialist Protomed has brought together key figures from the pharma, healthcare and pharmacy arenas to debate the future of medication management (22 October). Following recent news
SuperGen and GlaxoSmithKline have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets. Under the terms of the deal, SuperGen will progress
NPS Pharmaceuticals has reported additional data from a phase 3 study supporting the efficacy of Gattex (teduglutide) in patients with parenteral nutrition (PN)-dependent short bowel syndrome (SBS). Data
Horizon Therapeutics has presented an analysis from two pivotal phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine. The
The US Patent and Trademark Office (USPTO) has notified ExonHit of its intent to issue a re-examination certificate in connection with ExonHit’s US Patent n° 6881571 directed to
Pharmalink has been granted Japanese Patent No 4326696, for its product Nefecon. It is being developed to treat IgA nephropathy. Counterparts of the patent have been issued for
Merck KGaA has announced that group total revenues rose 2.7% in the third quarter to E1,944m from E1,893m in the year-ago quarter. The group’s operating result declined by
Ranbaxy Laboratories, an Indian major, has posted net sale of $356m for Q3, 2009, a de-growth of 18% over Q3, 2008. EBITDA was $45m, a margin of 13%